White on black - Original.png
  • Home

  • Research

    • Basilea
    • Diurnal Group
  • About

  • Services

  • Contact

  • Partners

  • Sign up

  • Blog

  • More

    Use tab to navigate through the menu items.
    • All Posts
    Search
    Brian White
    • Apr 27

    Basilea - Boosting the anti-fungal franchise

    104
    bw2078
    • Apr 25

    Diurnal Group - Efmody set for Swiss launch with EffRx

    75
    Brian White
    • Apr 20

    Diurnal Group - European commercial roll-out continues

    54
    Andrew Keith
    • Apr 1

    Diurnal Group - SMC decision, financial results and outlook

    114
    Brian White
    • Mar 30

    Diurnal Group - Commercial rollout continues

    80
    Andrew Keith
    • Mar 10

    Basilea - Refocusing on anti-infectives

    173
    Brian White
    • Mar 8

    Diurnal Group - SMC decision another hurdle to jump

    167
    Brian White
    • Feb 15

    Basilea - Strategic repositioning

    169
    Andrew Keith
    • Feb 14

    Diurnal Group - The AI and TRT opportunities

    142
    Brian White
    • Feb 10

    Diurnal Group - Efmody moving into larger AI disorder

    90
    Brian White
    • Jan 26

    Diurnal Group - Trading update ahead of R&D day

    153
    Andrew Keith
    • Jan 24

    Basilea - Phase 2 data on derazantinib at ASCO

    122
    Brian White
    • Jan 13

    Basilea - Fleshing out the Chinese Cresemba franchise

    80
    Brian White
    • Jan 11

    Basilea - ERADICATE enrolment completed

    97
    Brian White
    • Jan 11

    Diurnal business update - much to look forward to

    179
    Brian White
    • Jan 10

    Basilea - 2021 trading update provides financial reassurance

    107
    Brian White
    • Jan 7

    Basilea - Cresemba milestone provides a strong start to 2022

    120
    Brian White
    • Dec 21, 2021

    Basilea - Cresemba's China approval

    70
    Brian White
    • Dec 17, 2021

    Basilea - A burgeoning oncology pipeline

    133
    Andrew Keith
    • Dec 14, 2021

    Diurnal Group - Efmody 2022

    139
    1
    234

    Calvine Partners LLP is authorised and regulated by the Financial Conduct Authority

    Calvine Partners LLP, Partnership No. SO306987

    Registered address: 23 Melville Street, Edinburgh, EH3 7PE

    Privacy Policy

    Linkedin%20icon_edited.png